111 related articles for article (PubMed ID: 22739170)
41. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
Sood R; Carloss H; Kerr R; Lopez J; Lee M; Druck M; Walters IB; Noga SJ
Am J Hematol; 2009 Oct; 84(10):657-60. PubMed ID: 19731393
[TBL] [Abstract][Full Text] [Related]
42. Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group.
Walter-Croneck A; Grzasko N; Soroka-Wojtaszko M; Jurczyszyn A; Torosian T; Rymko M; Nowicki A; Druzd-Sitek A; Lech-Maranda E; Madro E; Zielinska P; Grygoruk-Wisniowska I; Blonska D; Usnarska-Zubkiewicz L; Potoczek S; Iskierka E; Masternak A; Holojda J; Dawidowska D; Gawron L; Barchnicka A; Olszewska-Szopa M; Rybicka M; Gontarska A; Jachalska A; Rzepecki P; Subocz E; Boguradzki P; Charlinski G; Dzierzak-Mietla M; Wisniewska-Piaty K; Swistek W; Kopacz A; Blajer-Olszewska B; Swiderska A; Dmoszynska A
Leuk Res; 2014 Jul; 38(7):788-94. PubMed ID: 24862794
[TBL] [Abstract][Full Text] [Related]
43. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.
Jagannath S; Durie BG; Wolf JL; Camacho ES; Irwin D; Lutzky J; McKinley M; Potts P; Gabayan AE; Mazumder A; Crowley J; Vescio R
Br J Haematol; 2009 Sep; 146(6):619-26. PubMed ID: 19622094
[TBL] [Abstract][Full Text] [Related]
44. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma.
Kim SJ; Kim K; Kim BS; Lee HJ; Kim H; Lee NR; Nam SH; Kwon JH; Kim HJ; Sohn SK; Won JH; Lee JH; Suh C; Yoon SS; Kim HJ; Kim I; Do YR; Lee WS; Joo YD; Shin HJ;
Clin Lymphoma Myeloma; 2008 Aug; 8(4):237-40. PubMed ID: 18765311
[TBL] [Abstract][Full Text] [Related]
45. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
46. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
[TBL] [Abstract][Full Text] [Related]
47. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
Richardson P; Jagannath S; Colson K
Clin Adv Hematol Oncol; 2006 May; 4(5):1; discussion 8; suppl 13. PubMed ID: 16830422
[TBL] [Abstract][Full Text] [Related]
48. Bortezomib: new drug. A last resort in myeloma: modest efficacy, major risks.
Prescrire Int; 2005 Jun; 14(77):94-8. PubMed ID: 15981389
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
Fukushima T; Nakamura T; Iwao H; Nakajima A; Miki M; Sato T; Sakai T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Nakajima H; Motoo Y; Umehara H
Anticancer Res; 2011 Jun; 31(6):2297-302. PubMed ID: 21737655
[TBL] [Abstract][Full Text] [Related]
50. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
51. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
Dimopoulos MA; Christoulas D; Roussou M; Kastritis E; Migkou M; Gavriatopoulou M; Matsouka C; Mparmparoussi D; Psimenou E; Grapsa I; Efstathiou E; Terpos E
Eur J Haematol; 2010 Jul; 85(1):1-5. PubMed ID: 20192988
[TBL] [Abstract][Full Text] [Related]
52. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
[TBL] [Abstract][Full Text] [Related]
53. [Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology].
Gotoh A; Ohyashiki K; Oshimi K; Usui N; Hotta T; Dan K; Ikeda Y; ;
Rinsho Ketsueki; 2006 Dec; 47(12):1521-7. PubMed ID: 17233470
[TBL] [Abstract][Full Text] [Related]
54. A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment.
Liu A; Yang G; Geng C; Wang H; Li L; Li Y; Wu Y; Tian Y; Leng Y; Wang G; Gao W; Chen W
Acta Haematol; 2016; 135(3):140-5. PubMed ID: 26587903
[TBL] [Abstract][Full Text] [Related]
55. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
[TBL] [Abstract][Full Text] [Related]
56. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
57. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
58. Pathogenesis and treatment of renal failure in multiple myeloma.
Dimopoulos MA; Kastritis E; Rosinol L; Bladé J; Ludwig H
Leukemia; 2008 Aug; 22(8):1485-93. PubMed ID: 18528426
[TBL] [Abstract][Full Text] [Related]
59. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Richardson PG; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Boral AL; Esseltine DL; Wen PY; Amato AA; Anderson KC; San Miguel J
Br J Haematol; 2009 Mar; 144(6):895-903. PubMed ID: 19170677
[TBL] [Abstract][Full Text] [Related]
60. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.
Manochakian R; Miller KC; Chanan-Khan AA
Oncologist; 2007 Aug; 12(8):978-90. PubMed ID: 17766658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]